Summary
Other Scenarios:
- MRK - HON
- MRK - UGP
- HON - SVYZY
- UGP - SVYZY
| Buyer: | Merck & Co Inc (MRK) | Last Price: | 38.03 | Market Cap.: | 117.16B |
|---|---|---|---|---|---|
| Target: | Solvay SA (SVYZY) | Last Price: | 12.55 | Market Cap.: | 1.06B |
Lines of Business Summary:
- Merck & Co Inc (MRK) competes in 2 industries and 287 product/service groups
- Solvay SA (SVYZY) competes in 3 industries and 26 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Merck & Co Inc (MRK) has 7 and Solvay SA (SVYZY) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Business and Public Services |
|
621 | |
|
Consumer |
|
890 | |
|
Healthcare |
|
|
731 |
|
Industrial and Materials |
|
888 |
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 272)n/a |
Target (Total: 21)n/a |
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 61)
|
Target (Total: 12)
|
Buyer (Total: 28)
|
Target (Total: 15)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 91,000 | 28,204 |
| Revenue Per Employee | 518,484.3 | 381,201.4 |
| Total Revenue | 11,731.0 | 3,337.0 |
| Total Expenses | 9,224.0 | 3,135.0 |
Other Revenue
|
n/a | 98.0 |
|
Cost of Revenue
|
4,037.0 | 2,669.0 |
|
SG&A Expense
|
2,999.0 | 277.0 |
|
Research & Development
|
1,808.0 | 64.0 |
|
Other Operating Expense
|
-45.0 | 40.0 |
|
Operating Income
|
2,507.0 | 202.0 |
|
Unusual Income
|
348.0 | 114.0 |
|
LT Debt to Capital
|
21.73 | 35.29 |
|
Fwd P/E
|
10.05 | n/a |
|
Fwd P/Rev
|
2.51 | n/a |
| Book Value | 54,860.0 | 6,203.0 |
|
Curr Portion of LTD/Cap Lease
|
2,930.0 | 843.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Industrial and Materials > Materials > Chemicals > Specialty and Performance Chemicals
Business Description
Buyer
Merck & Co., Inc. (Merck) is a global health care company. Merck delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets through its joint ventures. Merck?s operates in four segments: the Pharmaceutical, Animal Health, Consumer Care and Alliances segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions.
Target
Solvay SA (Solvay) is Belgium-based, internationally operating chemical industrial group. Solvay's Chemicals division produces materials for high tech applications such as electronics, barium and strontium compounds, calcium chloride, caustic soda, chlorinated products, fluor products, magnesium products, peroxygen products, polyglycerols, precipitated calcium carbonate, soda ash and sodium bicarbonate. The Plastics division produces specialty polymers for the aerospace, energy, automotive and healthcare industries, among others. The Plastics division further includes vinyls for building & construction, consumer goods, healthcare and wire & cable, and plastic pipes and fittings (Pipelife). The New Business Development division, founded in 2010, focuses on fostering new, strategic technologies through research and development, partnering with other companies, supporting start-ups and investments in venture capital funds. Solvay is active in 40 countries worldwide.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
65.04 | 21.46 |
|
Operating Margin %
|
16.83 | 7.79 |
|
Quick Ratio
|
1.46 | 1.59 |
|
Current Ratio
|
2.07 | 1.66 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 105,509.0 | 19,516.0 |
| Return on Equity % | 51.68 | 43.33 |
| Return on Assets % | 26.87 | 13.77 |
|
Cash+ ST Inv. Per Share
|
5.06 | 45.16 |
| Total Debt | 18,158.0 | 4,226.0 |
| Total Debt to Equity % | 33.1 | 68.13 |
| Total Debt to Tangible Equity % | 187.12 | 217.05 |
|
Debt to Asset %
|
17.21 | 21.65 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
Business and Public Services |
|
|
Waste Management Services |
|
|
|
Hazardous Materials Disposal
Collection, processing, and disposal of hazardous waste.
|
|
|
|
Other Waste Services
Other waste services, including soil remediation and wastewater residual management, logistics management services, waste-to-energy services, and secure waste processing services (processing of commercially sensitive, patent protected products), environmental consulting, and other environmental services.
Target Products:
|
|
|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, sanitary/personal care paper (tissues), shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Medical Devices |
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Industrial and Materials |
|
|
|
Industrial Manufacturing |
|
|
|
Electrical Equipment and Power Systems
Heavy-duty and infrastructure equipment and machinery that generate, transmit, and distribute electric power. It also contains electric lighting equipment and components, as well as products enabling end-user use and management of electric power.
|
|
|
|
Materials |
|
|
|
Chemicals
The Chemicals Subsector includes companies that manufacture basic, intermediate, specialty, and performance chemicals.
|
|
|
|
Construction Materials
The Construction Materials Subsector includes companies that manufacture heavy building materials, aggregates, fabricated wood products, architectural and infrastructure components.
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Business and Public Services |
|
|
|
Waste Management Services |
|
|
Hazardous Materials Disposal |
|
|
|
Hazardous/Industrial Waste
Hazardous and industrial waste processing (includes non-hazardous waste which cannot be economically recycled or reused) provided to commercial and government entities, such as medical institutions, energy utilities, steel mills, refineries and chemical production facilities. Also includes NOX emission control services and technologies provided to coal burning energy utilities.
Target Products:
|
|
|
|
Other Waste Services
Other waste services, including soil remediation and wastewater residual management, logistics management services, waste-to-energy services, and secure waste processing services (processing of commercially sensitive, patent protected products), environmental consulting, and other environmental services.
Target Products:
|
|
|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
|
Personal Care and Cleaning Products |
|
|
|
Oral Care
Oral Care products, including Toothpaste, Mouthwash, and denture adhesive.
Buyer Products:
|
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines/Mast Cell Stabilizers
Therapeutics that treat allergy symptoms by inhibiting the release of histamine and other immune mediators.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by suppressing inflammation and working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Vaccine Adjuvants
Therapeutic substances that ameliorate an immune response to treat allergies.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Acute Coronary Syndrome (ACS) |
|
|
|
Anticoagulating Agents |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Glycoprotein IIb/IIIa Receptor Blocking Agents
Therapeutics that treat acute coronary syndrome by blocking the receptor that allows platelets to clump together.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors (CETP)/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the incidence of acute coronary syndrome (ACS) by blocking cholesterol synthesis and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Glycoprotein IIb/IIIa Receptor Blocking Agents
Therapeutics that treat angina by blocking the receptor that allows platelets to clump together.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Anticoagulating Agents |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Glycoprotein IIb/IIIa Receptor Blocking Agents
Therapeutics that treat myocardial infarction by preventing various adhesive factors from attaching to the specific receptor and causing platelet aggregation.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors |
|
|
|
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors/Statins
Therapeutics that treat atherosclerosis by inhibiting the release of fatty acids from adipose tissue, blocking the effect of prostaglandin, and preventing cholesterol synthesis.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that reduce the risk of stroke by reducing high blood pressure through blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Buyer Products:
|
|
|
|
Pemphigus Vulgaris |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat Pemphigus Vulgaris by suppressing inflammation through inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
Acid Neutralizing Agents/H2 Receptor Antagonists
Therapeutics that treat heartburn by neutralizing stomach acid and blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Stool Softeners/Stimulants
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body as well as stimulating bowel contractions.
Buyer Products:
|
|
|
|
Impacted Bowels |
|
|
|
Stool Softeners
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat Crohn's Disease by inhibiting the action of Tumor Necrosis Factor (TNF), a key component of the inflammation process.
Buyer Products:
|
|
|
|
Ulcerative Colitis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ulcerative colitis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that treat hepatitis by binding to and blocking the action of protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Wilson`s Disease |
|
|
|
Chelating Agents
Therapeutics that treat Wilson's Disease by binding to and removing copper.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Diabetic Foot Ulcers |
|
|
|
Carbapenems
Therapeutics that treat foot ulcers by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides/Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that control high blood sugar by stimulating the release of insulin and by modifying gastric emptying, insulin secretion, and glucagon secretion.
Buyer Products:
|
|
|
|
Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that treat non-insulin dependent diabetes by inhibiting the action of dipeptidyl peptidase, thereby increasing the level of glucagon-like peptide-1 (GLP-1). GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Buyer Products:
|
|
|
|
Dipeptidyl Peptidase (DPP) Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat non-insulin dependent diabetes and high cholesterol by inhibiting both the synthesis of cholesterol with a statin, and inhibitingthe action of dipeptidyl peptidase, thereby increasing the level of glucagon-like peptide 1 (GLP-1). GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Buyer Products:
|
|
|
|
Dipeptidyl Peptidase (DPP) Inhibitors/PPAR Agonists
Therapeutics that treat non-insulin dependent diabetes by inhibiting the action of dipeptidyl peptidase, thereby increasing the level of glucagon-like peptide-1 (GLP-1), and sensitizing organs to insulin.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Betamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat gouty arthritis by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat gouty arthritis by preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Gonadotropins
Therapeutics that treat undescended testes by stimulating sex hormone secretion from the gonads.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that are synthetic estrogen analogues that are similar in certain aspect to natural estrogen.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat symptoms of menopause by inhibiting the action of serotonin.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Hypoprothrombinemia |
|
|
|
Vitamin K Analogs
Therapeutics that treat the deficiency of coagulation factor II.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Myelodysplastic Syndromes (MDS) |
|
|
|
Farnesyl Transferase Inhibitors
Therapeutics that treat myelodysplastic syndrome by inhibiting the action of farnesyl transferase, an enzyme necessary for cell division.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Psoriatic Arthritis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by
interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Crohn`s Disease |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat inflammation of the gastrointestinal tract by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Ulcerative Colitis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ulcerative colitis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Carbapenems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Lipopeptides
Therapeutics that treat bacterial infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Ophthalmology |
|
|
|
Conjunctivitis |
|
|
|
Macrolides
Therapeutics that treat inflammation of the clear membrane outside the eye by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumonia |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Onchocerciasis (River Blindness) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections characterize by worm filled nodules under the skin and itching.
Buyer Products:
|
|
|
|
Strongyloidiasis (Threadworm) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections of the intestines leading to mild to severe diarrhea.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Echinocandins
Therapeutics that treat fungal infections by inhibiting the synthesis of a major cell wall component.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation by preventing the accumulation of inflammatory cells like leukocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation by preventing the accumulation of inflammatory cells like leukocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Imidazoles/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide and suppressing inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Echinocandins
Therapeutics that treat fungal infections due to candidiasis through a broad spectrum fungicidal action.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.
Buyer Products:
|
|
|
|
Papillomavirus |
|
|
|
Verrucae (Warts) |
|
|
|
Interferons
Therapeutics that treat warts by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.
Buyer Products:
|
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that treat hepatitis by binding to and blocking the action of protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.
Buyer Products:
|
|
|
|
Viral |
|
|
|
Combination |
|
|
|
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.
Buyer Products:
|
|
|
|
Measles/Mumps/Rubella/Varicella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, rubella, and varicella.
Buyer Products:
|
|
|
|
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella.
.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Hepatitis A
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis A virus.
Buyer Products:
|
|
|
|
Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis B virus.
Buyer Products:
|
|
|
|
Herpes Zoster (Shingles)
Therapeutics that prevent or treat viral infections that cause shingles in adults.
Buyer Products:
|
|
|
|
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.
Buyer Products:
|
|
|
|
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.
Buyer Products:
|
|
|
|
Mumps
Therapeutics that prevent or treat viral infections characterized by swelling of salivary glands below the ear by producing or artificially increasing immunity to the mumps virus.
Buyer Products:
|
|
|
|
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.
Buyer Products:
|
|
|
|
Rotavirus
Therapeutics that prevent or treat viral infections that cause severe dehydrating diarrhea in children by producing or artificially increasing immunity to the rotavirus.
Buyer Products:
|
|
|
|
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.
Buyer Products:
|
|
|
|
Varicella-Zoster Virus (Chicken Pox)
Therapeutics that prevent or treat viral infections that cause a blistery red rash by producing or artificially increasing immunity to the Varicella Zoster virus.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Cathepsin K Inhibitors
Therapeutics that treat osteoporosis by inhibiting the formation of cathepsin K, resulting in increased bone mineral density.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors/Vitamin D Analogs
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts and by increasing calcium absorption.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ankylosing spondylitis interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat ankylosing spondylitis by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ankylosing spondylitis by blocking the effect of TNF-alpha, a pro-inflammatory molecule.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat gouty arthritis by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Psoriatic Arthritis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by
interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
CGRP Receptor Antagonists
Therapeutics that treat vascular/migraine headaches by reducing the release of calcitonin gene-related peptide (CGRP).
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat acute migraine by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Serotonin/Dopamine Receptor Blocking Agents
Therapeutics that treat bipolar disorders by blocking serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Serotonin/Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Orexin Receptor Antagonists
Therapeutics that treat insomnia by inhibiting the action of orexin.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat insomnia by inhibiting the action of serotonin.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Gonadotropins
Therapeutics that treat difficulties in conceiving by stimulating sex hormone secretion from the female gonads.
Buyer Products:
|
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Dermatology |
|
|
|
Kaposi`s Sarcoma |
|
|
|
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Malignant Melanoma |
|
|
|
Interferons
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Anal Cancer |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of anal cancer.
Buyer Products:
|
|
|
|
Endocrinology |
|
|
|
Adrenal Glands |
|
|
|
Pheochromocytoma |
|
|
|
Tyrosine Hydroxylase Inhibitors
Therapeutics that treat adrenal gland tumors that produce epinephrine and norepinephrine by inhibiting the production of epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphocytic |
|
|
|
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Hairy Cell |
|
|
|
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Chronic |
|
|
|
Myelogenous (CML) |
|
|
|
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of myeliod cells by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Cutaneous T-Cell Lymphoma (CTCL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Histone Deacetylase (HDAC) Inhibitors
Therapeutics that treat and manage T-Cell lymphomas of the skin by inhibiting deacetylation of histone, leading to expression of genes responsible for tumor growth regulation and apoptosis.
Buyer Products:
|
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division but that are not curative.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Interferons
Therapeutics that treat and manage lymphomas of B-cells and T-cells by providing a naturally occurring protein that stimulates the immune system.
Buyer Products:
|
|
|
|
Multiple Myeloma (Plasma Cell Cancer) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage multiple myeloma by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Ewing`s Sarcoma (Primitive Neuroepithelial Cancer) |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat Ewing's Sarcoma by interacting with DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage metastatic bone cancer by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Rhabdomyosarcoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers arising from striated muscle by interacting with DNA.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Glioma |
|
|
|
Astrocytoma |
|
|
|
Alkylating Agents |
|
|
|
Imidazotetrazines
Therapeutics that treat and manage cancer of the astrocyte cells in the brain and spinal cord.
Buyer Products:
|
|
|
|
Glioblastoma |
|
|
|
Alkylating Agents |
|
|
|
Imidazotetrazines
Therapeutics that treat and manage cancer of the glial cells.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat kidney cancer by interacting with DNA.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Small Molecule Drug Conjugates (SMDC)
Therrapeutics comprised of a receptor targeting ligand and drug payload that bind cancerous cells and release the drug payload within them.
Buyer Products:
|
|
|
|
Testicular Cancer |
|
|
|
Metastatic |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat testicular cancers that have spread beyond their original tumor site by interacting with DNA.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Vaccines
Therapeutics that are meant to promote an immune response against a patient's bladder cancer.
Buyer Products:
|
|
|
|
Uterine Cancer |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the uteris by interacting with DNA.
Buyer Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Papillomavirus Vaccines
Therapeutics that promote an immune response against the Papillomavirus that are involved in the pathogenesis of vaginal and vulvar cancers.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Immunosuppressants
Therapeutics that suppress the immune system pathways that can lead to dryness of the eye.
Buyer Products:
|
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Buyer Products:
|
|
|
|
Glaucoma |
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Carbonic Anhydrase Inhibitors/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Prostanoid Selective FP Receptor Agonists
Therapeutics that increase the outflow of fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Vasoconstricting Agents
Therapeutics that prevent inflammation by constricting the blood vessels.
Buyer Products:
|
|
|
|
Non-Degenerative Disorders |
|
|
|
Allergic Conjunctivitis |
|
|
|
Antihistamines/Mast Cell Stabilizers
Therapeutics that treat allergic conjunctivitis by inhibiting the release of histamine and other immune mediators from cells involved in allergic response.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Buyer Products:
|
|
|
|
Reversal |
|
|
|
Selective Relaxant Binding Agents
Therapeutics that reverse general anesthesia by forming a complex with steroidal nondepolarizing neuromuscular blockers in the plasma and lowering the effective concentration available at the receptors.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lungs with steroids and that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Leukotriene Receptor Antagonists
Therapeutics that treat asthma by reducing inflammation in the lung passages by working on certain receptors involved in the immune process.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Agonists/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that are used to prevent COPD attacks by preventing inflammation and stimulating beta adrenergic receptors.
Buyer Products:
|
|
|
|
Cystic Fibrosis (CF) |
|
|
|
P2Y2 Agonists
Therapeutics that relieve symptoms of cystic fibrosis by enhancing mucosal hydration and mucociliary clearance in airways by activating receptors on the mucosal surface.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat allergic reactions by suppressing inflammation, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antihistamines/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Antitussives/Expectorants
Therapeutics that treat coughs and colds by suppressing coughs and helping ejection of the mucous.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
|
Nasal Polyposis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the polyps in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Ischemia |
|
|
|
Adenosine Regulating Agents (ARA)
Therapeutics that treat the obstruction of a blood vessel by increasing the availability of adenosine locally in ischemic tissues.
Buyer Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Glycoprotein IIb/IIIa Receptor Blocking Agents
These therapeutics prevent the clotting of blood before coronary artery procedures are performed through the skin.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Endocrinology |
|
|
|
Adrenal Glands |
|
|
|
Tyrosine Hydroxylase Inhibitors
Therapeutics that are used prior to specific surgical procedures to remove high levels of epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Narcotics |
|
|
|
Opioid Analgesics
Therapeutics that treat narcotic withdrawal by providing the body with a milder opioid substitute.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the breakdown of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Cryptorchidism |
|
|
|
Gonadotropins
Therapeutics that treat undescended testes by stimulating sex hormone secretion from the gonads.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Gonadotropins
Therapeutics that treat hypogonadism by providing gonadotropins which stimulate sex hormone secretion from the gonads.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Neurogenic Bladder Disease |
|
|
|
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Cardiovascular |
|
|
|
Cholesterol Absorption Inhibitors
Therapeutics that treat and/or prevent cardiovascular events arising from the decline in kidney function associated with chronic renal failure by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat and/or prevent cardiovascular events arising from the decline in kidney function associated with chronic renal failure through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also by inhibiting the absorption of cholesterol.
Buyer Products:
|
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Cystinuria |
|
|
|
Chelating Agents
Therapeutics that treat an inherited abnormality of kidney function which results in increased excretion of certain amino acids by forming complexes with these amino acids to decrease their excretion.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Obstetrics/Gynecology |
|
|
|
Treatment |
|
|
|
Procedure Specific |
|
|
|
Contraception |
|
|
|
Implants
Medical devices implanted into the body to prevent pregnancy.
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Biopharmaceutical OEM |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Medical Device OEM
Contract Manufacturing Organizations that manufacture (and/or design, develop) medical devices and products for other organizations.
Target Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Industrial and Materials |
|
|
|
Industrial Manufacturing |
|
|
|
Electrical Equipment and Power Systems |
|
|
|
Power Generation/Support Products |
|
|
|
Renewable Energy and Distributed Generation |
|
|
|
Fuel Cell Equipment and Technology
Power equipment based on emerging fuel cell (or proton exchange membrane) energy technology. Products may be found in transportation equipment, portable electronic devices, distributed power generation and other applications.
Target Products:
|
|
|
|
Materials |
|
|
|
Chemicals |
|
|
|
Commodity Chemicals |
|
|
|
Inorganic Chemicals |
|
|
|
Other Inorganic Chemicals
Includes companies engaged in the manufacturing of basic and intermediate inorganic chemicals, such as compounds of ammonium, bromine, chromium, potassium, sodium, sulfur, nitrogen, chlor-alkalis, and others.
Target Products:
|
|
|
|
Organic and Petrochemicals |
|
|
|
Other Organic Chemicals
Includes companies engaged in the manufacturing of other basic and intermediate organic chemicals, such as industrial alcohol, acrylate, vinyl chloride monomer, vinyl acetate monomer, formaldehyde, enzymes, proteins, fatty acids, gum and wood based chemicals, and others. Ethanol is excluded from this level.
Target Products:
|
|
|
|
Specialty and Performance Chemicals |
|
|
|
Additives |
|
|
|
Flavors and Fragrances |
|
|
|
Flavors and Other Food Additives
Companies engaged in the manufacturing of flavors and other food and beverages additives.
Target Products:
|
|
|
|
Fragrances and Other Personal Care Additives
Companies engaged in manufacturing of fragrance and other additives for household and personal care products.
Target Products:
|
|
|
|
Other Performance Additives
Includes companies engaged in the manufacturing of other performance additives, chemicals added to a variety of materials to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Polymer Additives
Includes companies engaged in the manufacturing of polymer additives, chemicals added to polymers to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Pulp and Paper Additives
Includes companies engaged in the manufacturing of pulp and paper additives, chemicals added to pulp and paper to impart specific beneficial properties or to enhance performance.
Target Products:
|
|
|
|
Adhesives, Sealants, Coatings and Paints |
|
|
|
Coatings and Paints |
|
|
|
Coatings
Includes companies engaged in the manufacturing of coatings used in a wide range of industries.
Target Products:
|
|
|
|
Agrochemicals |
|
|
|
Other Agrochemicals
Includes companies engaged in the manufacturing of other agrochemicals used to improve and protect crop yield.
Target Products:
|
|
|
|
Cleaning and Sanitizing Agents |
|
|
|
Soaps, Detergents, And Biocides
Includes companies engaged in the manufacturing of industrial cleaning agents used in a wide range of industries, as well as inputs for these products. Industrial biocides used to destroy undesirable microorganisms in a wide range of applications are also included.
Target Products:
|
|
|
|
Water Treatment Agents
Includes companies engaged in the manufacturing of water treatment agents used to sanitize or purify contaminated water.
Target Products:
|
|
|
|
Fibers and Polymers |
|
|
|
Other Fibers and Polymers
Includes companies engaged in the manufacturing of other fibers and polymers not classified as plastic or rubber.
Target Products:
|
|
|
|
Plastic Resins and Materials
Includes companies engaged in the manufacturing of plastic resins and materials, such as polyethylene, polypropylene, polystyrene, polycarbonates, thermoplastic polyester, polyamide, acrylonitrile butadiene styrene and others.
Target Products:
|
|
|
|
Other Specialty and Performance Chemicals |
|
|
|
Electronic Materials
Materials used to manufacture electronic products such as printed circuit boards and batteries. Materials include laminates and specialty foams.
Target Products:
|
|
|
|
Film and Imaging Chemicals
Includes companies engaged in the manufacturing of film and imaging chemicals.
Target Products:
|
|
|
|
Nanotechnology Materials
Includes companies engaged in the manufacturing of nanoscopic materials by using advanced molecular and atomic technologies.
Target Products:
|
|
|
|
Construction Materials |
|
|
|
Architectural and Infrastructure Components |
|
|
|
Architectural Components |
|
|
|
Plumbing
Companies which manufacture plumbing related building products.
Target Products:
|
|
|
|
Infrastructure Components |
|
|
|
Pipes and Pipe Fittings |
|
|
|
Agricultural Irrigation
Includes metal, plastic, and concrete pipes and pipe fittings used in agricultural irrigation.
Target Products:
|
|
|
|
Other Industrial Pipes & Pipe Fittings
Includes metal, plastic, and concrete pipes and pipe fittings used for other industrial purposes.
Target Products:
|
|
|
|
Petroleum & Petrochemicals
Includes metal, plastic, and concrete pipes and pipe fittings used in petroleum and petrochemicals transportation.
Target Products:
|
|
|
|
Utilities
Includes metal, plastic, and concrete pipes and pipe fittings used in municipal water transportation, sewage transportation, natural gas transportation, etc.
Target Products:
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Honeywell International Inc
|
|
n/a | 45,810.995 | 21.10 | 13.02 | 1.23 | 1.19 | n/a | |
|
Targacept Inc
|
|
n/a | 153.872 | n/a | -11.82 | 1.89 | 2.66 | 0.86 | |
|
Furiex Pharmaceuticals Inc
|
|
n/a | 134.979 | n/a | -4.70 | 19.93 | 5.92 | 7.89 | |
| Buyer | |||||||||
|
Pfizer Inc
|
|
n/a | 176,718.154 | 12.80 | 10.33 | 1.77 | 2.94 | n/a | |
|
Roche Holding AG
|
|
n/a | 145,117.557 | 25.19 | 10.28 | 2.12 | 3.03 | n/a | |
|
GlaxoSmithKline PLC
|
|
n/a | 115,869.873 | 15.41 | 11.55 | 3.65 | 2.56 | n/a | |
| Target | |||||||||
|
Honeywell International Inc
|
|
n/a | 45,810.995 | 21.10 | 13.02 | 1.23 | 1.19 | n/a | |
|
Ultrapar Participacoes SA
|
|
n/a | 18,934.778 | 50.03 | 18.66 | 0.44 | 0.63 | 4.69 | |
|
PPG Industries Inc
|
|
n/a | 16,569.360 | 19.24 | 13.27 | 1.10 | 1.06 | n/a | |
|
Akzo Nobel NV
|
|
n/a | 11,613.326 | 21.47 | 11.74 | 0.66 | 0.56 | 6.28 | |
|
FMC Corp
|
|
n/a | 7,595.005 | 24.80 | 15.15 | 2.16 | 2.04 | 7.11 | |
|
Celanese Corp
|
|
n/a | 7,035.476 | 10.87 | 9.80 | 1.03 | 1.00 | 12.65 | |
|
Eastman Chemical Co
|
|
n/a | 6,975.120 | 8.39 | 9.62 | 0.96 | 0.90 | 3.44 | |
|
Braskem SA
|
|
n/a | 5,102.602 | n/a | 25.57 | 0.19 | 0.21 | 0.74 | |
|
Rockwood Holdings Inc
|
|
n/a | 4,056.406 | 13.08 | 11.57 | 1.11 | 1.07 | 33.44 | |
|
Tetra Technologies Inc
|
|
n/a | 555.696 | 80.76 | 8.99 | 0.69 | 0.64 | 0.97 | |
|
Targacept Inc
|
|
n/a | 153.872 | n/a | -11.82 | 1.89 | 2.66 | 0.86 | |
|
Furiex Pharmaceuticals Inc
|
|
n/a | 134.979 | n/a | -4.70 | 19.93 | 5.92 | 7.89 | |
|
Fuel Tech Inc
|
|
n/a | 99.528 | 15.87 | 15.81 | 1.03 | 1.01 | 1.59 | |
|
ShengdaTech Inc
|
|
n/a | 4.878 | 0.20 | n/a | 0.04 | n/a | 0.03 | |
|
LANXESS AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Arkema
|
|
n/a | n/a | n/a | 7.24 | n/a | n/a | n/a | |
|
Elementis PLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Mexichem SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Grupo Pochteca SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Cardiome Pharma Corp
|
|
99.13% | 32.398 | n/a | -3.25 | 21.54 | 6.51 | 1.36 | |
|
Idera Pharmaceuticals Inc
|
|
29.60% | 29.289 | n/a | -1.22 | 557.82 | 15.20 | 1.63 | |
|
Heska Corporation
|
|
13.00% | 65.963 | 30.63 | 12.50 | 0.94 | 0.77 | 1.36 | |
|
Codexis Inc
|
|
10.00% | 117.769 | n/a | -6.22 | 0.95 | 0.92 | 1.42 | |
|
VirtualScopics Inc
|
|
5.00% | 36.054 | 60.85 | 31.00 | 2.52 | n/a | 5.23 | |
|
Biomed Realty Trust Inc
|
|
2.80% | 2,617.462 | 92.51 | 15.53 | 4.68 | 5.40 | 1.02 | |
|
Exelixis Inc
|
|
0.10% | 657.769 | 8.19 | -4.79 | 2.42 | 12.37 | 9.58 | |
|
Johnson & Johnson
|
|
n/a | 176,314.376 | 10.12 | 12.61 | 1.55 | 2.65 | n/a | |
|
Novartis SA
|
|
n/a | 145,820.038 | 16.87 | 10.02 | 2.47 | 2.53 | 104.31 | |
|
Astrazeneca PLC
|
|
n/a | 58,543.357 | 7.02 | 7.04 | 1.79 | 2.01 | 94.73 | |
|
E.I. Du Pont De Nemours & Co
|
|
n/a | 48,089.128 | 13.61 | 12.07 | 1.20 | 1.17 | n/a | |
|
Eli Lilly & Co
|
|
n/a | 47,766.248 | 11.08 | 12.77 | 1.99 | 2.13 | 4.99 | |
|
Publicis Groupe SA
|
|
n/a | 9,386.486 | 16.82 | 10.80 | 0.95 | 1.12 | n/a | |
| Target | |||||||||
|
Braskem SA
|
|
n/a | 5,102.602 | n/a | 25.57 | 0.19 | 0.21 | 0.74 | |
|
Technip (ex-Technip-Coflexip)
|
|
n/a | 2,758.440 | 4.21 | 17.19 | 0.32 | 0.26 | 0.73 | |
|
Light SA
|
|
n/a | 2,749.032 | 12.07 | n/a | 0.49 | n/a | n/a | |
|
Mills Estruturas e Servicos de Engenharia SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Elekeiroz SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
MRS Logística
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Qingdao Taineng Natural Gas Group Co., Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PT Lautan Luas Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Mexichem SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
L'Air Liquide
|
|
n/a | n/a | n/a | 13.47 | n/a | n/a | n/a | |
|
ICADE SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Unipar Participacoes SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Suhail Bahwan Group (Holding) LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Roche Holding AG
|
|
n/a | 145,117.557 | 25.19 | 10.28 | 2.12 | 3.03 | n/a | |
|
Sanofi
|
|
n/a | 96,915.321 | 19.01 | 9.11 | 2.27 | 2.11 | n/a | |
|
Astrazeneca PLC
|
|
n/a | 58,543.357 | 7.02 | 7.04 | 1.79 | 2.01 | 94.73 | |
|
McKesson Corp
|
|
n/a | 22,204.333 | 38.60 | 12.41 | 0.18 | 0.18 | n/a | |
|
Cardinal Health Inc
|
|
n/a | 14,896.420 | 14.43 | 13.20 | 0.14 | 0.14 | 7.97 | |
|
AmerisourceBergen Corp
|
|
n/a | 9,860.177 | 14.30 | 12.97 | 0.12 | 0.12 | 3.35 | |
|
Dr Reddy'S Laboratories Ltd
|
|
n/a | 5,185.959 | 0.62 | 16.20 | 0.10 | n/a | n/a | |
|
AU Optronics Corp
|
|
n/a | 3,875.073 | n/a | -4.76 | 0.04 | 0.30 | 0.02 | |
|
Salix Pharmaceuticals Ltd
|
|
n/a | 3,030.334 | 30.86 | 20.58 | 5.00 | 4.01 | 6.38 | |
| Target | |||||||||
|
Albemarle Corporation
|
|
n/a | 5,805.462 | 13.40 | 12.76 | 2.01 | 1.95 | 3.37 | |
|
Innophos Holdings Inc
|
|
n/a | 1,061.087 | 11.98 | 12.51 | 1.26 | 1.20 | n/a | |
|
Sciclone Pharmaceuticals Inc
|
|
n/a | 344.099 | 14.06 | 8.31 | 2.28 | 2.02 | 4.14 | |
|
KMG Chemicals Inc
|
|
n/a | 197.289 | 20.15 | 10.67 | 0.70 | 0.72 | 2.54 | |
|
Grupo Pochteca SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
British American Tobacco Chile Operaciones SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Petkim Petrokimya Holding AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Faes Farma SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Soda Sanayii AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Brenntag AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Suhail Bahwan Group (Holding) LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cia Tecidos Santanense SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Nadir Figueiredo Industria e Comercio SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cia Souza Cruz Industria e Comercio CRUZ
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Carboclor SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Faes Farma SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Suhail Bahwan Group (Holding) LLC
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 176,314.376 | 10.12 | 12.61 | 1.55 | 2.65 | n/a | |
|
Novartis SA
|
|
n/a | 145,820.038 | 16.87 | 10.02 | 2.47 | 2.53 | 104.31 | |
| Target | |||||||||
|
BASF SE
|
|
n/a | 69,253.294 | 9.59 | 9.10 | 0.85 | 0.75 | 5.67 | |
|
Deutsche Bank AG
|
|
n/a | 37,984.311 | 9.57 | 6.07 | 2.68 | 0.86 | 0.97 | |
|
Dow Chemical Co
|
|
n/a | 37,976.191 | 17.44 | 12.24 | 0.63 | 0.62 | 7.49 | |
|
Albemarle Corporation
|
|
n/a | 5,805.462 | 13.40 | 12.76 | 2.01 | 1.95 | 3.37 | |
|
Wienerberger AG
|
|
n/a | 1,234.031 | n/a | n/a | 0.56 | n/a | 0.69 | |
|
Innophos Holdings Inc
|
|
n/a | 1,061.087 | 11.98 | 12.51 | 1.26 | 1.20 | n/a | |
|
Arqule Inc
|
|
n/a | 347.615 | n/a | -20.31 | 8.20 | 8.37 | 12.60 | |
|
Sciclone Pharmaceuticals Inc
|
|
n/a | 344.099 | 14.06 | 8.31 | 2.28 | 2.02 | 4.14 | |
|
KMG Chemicals Inc
|
|
n/a | 197.289 | 20.15 | 10.67 | 0.70 | 0.72 | 2.54 | |
|
Solvay Indupa SAIC Solvay Indupa
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Huatai Group
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Nepes Corp
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
JSC SIBUR Holding
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Polyera Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Albanesi SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Tönsmeier Group
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Plextronics, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
ACAL Energy Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Amminex A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Vinythai Public Co Ltd
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Thin Film Electronics ASA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 48,198.0 | 15,039.0 | 63,237.0 |
|
Other Revenue
|
n/a | 98.0 | 98.0 |
| Total Revenue | 48,198.0 | 15,137.0 | 63,335.0 |
|
Cost of Revenue
|
16,849.0 | 11,888.0 | 28,737.0 |
|
SG&A Expense
|
13,252.0 | 1,182.0 | 14,434.0 |
|
Depreciation & Amortization
|
n/a | n/a | n/a |
|
Research & Development
|
7,739.0 | 283.0 | 8,022.0 |
|
Interest Expense
|
77.0 | n/a | 77.0 |
|
Other Operating Expense
|
-227.0 | 415.0 | 188.0 |
|
Unusual Expense (Income)
|
2,535.0 | 302.0 | 2,837.0 |
| Total Expenses | 40,087.0 | 13,958.0 | 54,045.0 |
|
Operating Income
|
8,111.0 | 1,179.0 | 9,290.0 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
n/a | 8.0 | 8.0 |
|
Other, Net
|
n/a | -274.0 | -274.0 |
| Income Before Taxes | 8,111.0 | 813.0 | 8,924.0 |
| Income Taxes | 1,023.0 | 141.0 | 1,164.0 |
| Income After Taxes | 7,088.0 | 672.0 | 7,760.0 |
| Minority Interest (IS) | -122.0 | -92.0 | -214.0 |
|
Net Income - Excl. Xord. Items
|
6,966.0 | 580.0 | 7,546.0 |
| Discontinued Operations | n/a | -81.0 | -81.0 |
|
Net Income - Incl. Xord. Items
|
6,966.0 | 499.0 | 7,465.0 |
|
Misc. Earnings Adjustment
|
-11.0 | n/a | -11.0 |
|
Income Avail. to Common
|
6,955.0 | 499.0 | 7,454.0 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
3,074.0 | 81.5 | 3,155.5 |
|
Basic EPS - Excl. Xord. Items
|
2.26 | 7.14 | 2.39 |
|
Basic EPS - Incl. Xord. Items
|
2.26 | 6.14 | 2.37 |
| Full Dilution Adjustment | n/a | n/a | n/a |
| Fully Diluted Shares Outstanding | 3,074.0 | 81.8 | 3,155.8 |
|
F.D. EPS - Excl. Xord. Items
|
2.26 | 7.11 | 2.39 |
|
F.D. EPS - Incl. Xord. Items
|
2.26 | 6.12 | 2.37 |
| Dividends Per Common Share | 1.18 | n/a | 1.18 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
14,656.0 | 1,752.0 | 16,408.0 |
|
ST Investments
|
910.0 | 1,943.0 | 2,853.0 |
|
Accounts Receivable
|
8,726.0 | 3,429.0 | 12,155.0 |
|
Inventory
|
6,339.0 | 1,512.0 | 7,851.0 |
|
Other Current Assets
|
3,713.0 | 748.0 | 4,461.0 |
|
Current Assets
|
34,344.0 | 7,441.0 | 41,785.0 |
|
PPE
|
32,821.0 | n/a | 32,821.0 |
|
Accum D&A
|
-16,697.0 | n/a | -16,697.0 |
|
PPE, Net
|
16,124.0 | 5,565.0 | 21,689.0 |
| Goodwill & Intangibles | 45,156.0 | 4,256.0 | 49,412.0 |
| Long Term Investments | 3,972.0 | 963.0 | 4,935.0 |
|
Note Receivable
|
n/a | 450.0 | 450.0 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
5,913.0 | 841.0 | 6,754.0 |
| Total Assets | 105,509.0 | 19,516.0 | 125,025.0 |
| Liabilities | |||
| Accounts Payable | 2,358.0 | 2,295.0 | 4,653.0 |
| Payable/Accrued | n/a | n/a | n/a |
| Accrued Expenses | 8,823.0 | n/a | 8,823.0 |
|
ST Debt
|
n/a | n/a | n/a |
|
Curr Port of LTD & Cap Lease Oblg
|
2,930.0 | 843.0 | 3,773.0 |
| Other (Current) Liabilities | 2,471.0 | 1,347.0 | 3,818.0 |
|
Current Liab.
|
16,582.0 | 4,485.0 | 21,067.0 |
|
LT Debt
|
15,228.0 | 3,383.0 | 18,611.0 |
|
Total LT Debt
|
15,228.0 | 3,383.0 | 18,611.0 |
| Minority Interest (BS) | 2,454.0 | 508.0 | 2,962.0 |
| Deferred Taxes | 16,385.0 | 784.0 | 17,169.0 |
|
Other LT Liab.
|
n/a | 4,151.0 | 4,151.0 |
|
Total Liabilities
|
50,649.0 | 13,311.0 | 63,960.0 |
| Shareholders Equity | |||
| Common Stock | 1,788.0 | 1,271.0 | 3,059.0 |
| Additional Paid in Capital | 40,652.0 | 18.0 | 40,670.0 |
| Retained Earnings | 39,441.0 | 5,751.0 | 45,192.0 |
| Unrealized Gain (Loss) | n/a | -249.0 | -249.0 |
| Treasure Stock | -23,804.0 | -192.0 | -23,996.0 |
| Other Equity | -3,217.0 | -396.0 | -3,613.0 |
|
Total Equity
|
54,860.0 | 6,203.0 | 61,063.0 |
|
Total Liab. & Equity
|
105,509.0 | 19,514.0 | 125,023.0 |
|
Shares Outstanding
|
3,042.0 | 81.2 | 3,123.2 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 7,088.0 | 538.0 | 7,626.0 |
| CF Depreciation | 7,386.0 | 571.0 | 7,957.0 |
| CF Deferred Taxes | -1,364.0 | n/a | -1,364.0 |
| Other Non-Cash Items | 879.0 | -182.0 | 697.0 |
| Change in Working Capital | -1,173.0 | 72.0 | -1,101.0 |
| Total Cash From Operating Activities | 12,816.0 | 999.0 | 13,815.0 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,730.0 | -694.0 | -2,424.0 |
| Other Investing Cash Flows | -1,535.0 | -3,982.0 | -5,517.0 |
| Total Cash From Investing Activities | -3,265.0 | -4,676.0 | -7,941.0 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -4,795.0 | -257.0 | -5,052.0 |
| Purchase Or Sale of Stock | -1,714.0 | 141.0 | -1,573.0 |
| Purchase and Retirement of Debt | 364.0 | -18.0 | 346.0 |
| Other Financing Cash Flow | -312.0 | 1,899.0 | 1,587.0 |
| Total Cash From Financing Activities | -6,457.0 | 1,765.0 | -4,692.0 |
| Exchange Rate Effects | -133.0 | 0.0 | -133.0 |
| Net Change in Cash | 2,961.0 | -1,910.0 | 1,051.0 |
| Cash Taxes Paid | 2,700.0 | 8.0 | 2,708.0 |
| Cash Interest Paid | 600.0 | n/a | 600.0 |